PMID
int64 35.7M
36.4M
| Title/Abstract
stringlengths 22
8.78k
| MeshTerms
stringlengths 7
101
| SemanticTypes
stringlengths 4
64
|
|---|---|---|---|
36,283,232
|
migrat transform soil mercuri karst region southwest china implic groundwat contamin guizhou provinc locat heart karst zone southwest china one largest karst area world given fragil surfac ecosystem high develop underground karst structur migrat transform soil hg may impact groundwat qualiti karst environ high hg background concentr studi examin vertic migrat transform soil mercuri hg two karst catchment huilong chenqi former contain high hg content associ miner latter repres region background hg result show soil hg pool huilong catchment high g wherea chenqi catchment g compar farmland soil forest soil show signific loss hg result l x ray absorpt near edg structur hg indic hgs primari miner hg ore gradual chang miner type soil format huilong catchment proport organ bound hg sr total hg decreas soil depth increas cm cm farmland soil profil forest soil profil proport ionic hg increas soil depth farmland soil profil forestland soil profil result tripl mix isotop model show soil hg account hg groundwat two catchment result studi indic potenti risk soil hg enter groundwat karst area
|
D008628;D060587
|
T070;T082;T131;T196;T081
|
36,283,231
|
effect dissolv organ matter bioavail toxic cadmium zebrafish larva determin base toxicokinet toxicodynam process presenc dissolv organ matter dom strong influenc bioavail metal aquat environ howev associ bind activ concentr dom composit well document lead uncertainti metal toxic assess creativ quantifi mitig acceler effect dom composit cadmium cd bioaccumul toxic zebrafish larva use abiot ligand abl biotic ligand bls toxicokinet toxicodynam tk td model bl tk td model could accur predict protect effect fulvic acid overestim complex capac citric acid model also could success simul protect effect nativ dom case natur water bodi china observ lc valu cd show peak effect nativ dom fraction compris hydrophil acid content mg l natur water site bl tk td model provid practic use inform identifi effect differ dom composit metal bioavail toxic aquat environ guid futur water manag polici aim control aquat heavi metal pollut
|
D002104;D014874
|
T131;T196
|
36,283,230
|
surfact sodium dodecyl sulfat enhanc degrad polystyren microplast energi save electrochem advanc oxid process eaop strategi microplast identifi kind emerg pollut potenti ecolog risk urgent endeavor find proper technolog remedi electrochem advanc oxid process eaop technolog exhibit robust perform remov various refractori organ pollut studi explor new remedi strategi polystyren microplast ps mps introduc sodium dodecyl sulfat sds enhanc degrad perform boron dope diamond bdd anod adopt eaop first investig degrad behavior sds bdd electrolysi accord sds half life various current densiti sds addit strategi eaop propos supplement sds mgl everi half life electrolysi except last cycl result indic sds addit great enhanc mps degrad rate h eaop time higher bdd electrolysi alon sds assist eaop also led obvious chang particl size morpholog function group mps treatment varieti alkyl cleavag oxid product identifi attribut strong attack oxid ie persulf mps enhanc persulf generat oxid adsorpt mps explain enhanc effect eaop strategi cost analysi result show surfact account total oper cost sds assist eaop general current studi provid new insight effect way improv eaop effici microplast
|
D000080545;D014874
|
T131;T122
|
36,283,177
|
design synthesi vitro evalu novel antifung triazol contain substitut triazol methoxyl side chain order develop new triazol deriv optim lead compound structur modif obtain seri rr substitut h triazol yl methoxi difluorophenyl h triazol yl butan ol compound target compound exhibit excel vitro antifung activ candida albican candida glabrata mic gml particular note compound high activ candida neoforman mic gml show broad spectrum antifung activ includ fluconazol resist candida auri addit compound demonstr inhibitori effect filament azol resist c albican isol moreov compound minim toxic huvec possess weak inhibitori effect human cypa cypd sar dock studi indic ortho substitut group termin phenyl ring promot compound improv antifung activ
|
D000935;D014230
|
T121;T195;T109
|
36,283,176
|
cc small molecular compound suppress multipl myeloma via upregul nur multipl myeloma mm hematolog malign plasma cell character product monoclon immunoglobulin protein despit signific advanc treatment mm remain incur disord owe resist chemotherapi refractori natur inhibitor histon deacetylas hdaci identifi promis therapeut drug cancer treatment present numer hdaci studi treatment mm monotherapi conjunct agent
|
D009101
|
T191
|
36,283,145
|
rocker profil design shoe improv pendular energi recoveri walk effect total mechan work rocker profil design shoe common use clinic set footwear reduc shoe pressur forefoot area gait depend rocker profil type ie toe heel negat doubl rocker affect lower limb kinemat kinet muscl electromyograph activ howev whether wear rocker profil shoe influenc dynam bodi centr mass bcom unknown use mathemat procedur combin lissaj contour fourier analysi describ trajectori bcom walk rocker profil rollingsol flat control shoe particip harmon amplitud phase compar use linear circular statist respect extern wext kinemat intern wint k total wtot mechan work mechan energi fraction recov pendular exchang potenti kinet energi also calcul rollingsol shoe yield greater wext p lt fraction pendular energi exchang p lt lower wint k p lt unchang wtot p rollingsol shoe led also greater mean height bcom p lt amplitud anteroposterior vertic symmetr mediolater nd th harmon p lt differ shoe found harmon phase p result indic rollingsol shoe enhanc invert pendulum like behaviour bcom walk alter total mechan work may result combin rocker profil design greater bcom height thicker sole shoe increas recoveri mechan energi step step transit mid stanc
|
D012775;D016138
|
T169;T056;T073
|
36,283,138
|
health facil risk factor multidrug resist gram negat bacteria critic ill patient covid relationship multidrug resist gram negat bacteria mdr gnb infect colon critic ill covid patient observ howev still poor understood studi evalu risk factor acquir mdr gnb patient sever covid intens care unit icu
|
D000086382;D003428;D016905
|
T047;T067
|
36,283,127
|
screen small molecul inhibitor rhoa protein alisma use onlin detect system target high throughput screen inhibitor natur product effect approach treatment cancer progress rhoa protein essenti mani signal pathway close relat occurr develop tumor far report screen small molecul inhibitor rhoa protein natur product studi onlin uhplc pda ms rhoa fld screen system establish first time identifi rhoa inhibitor medicin alisma use onlin system ad fluoresc probe protopin lz protein activ compon identifi alisma includ terpenoid bind abil evalu surfac plasmon reson experi activ repres compound test show anti prolif effect cancer cell mechanist studi show compound abl downregul cellular express rhoa associ protein studi provid potenti lead compound small molecul inhibitor rhoa protein cancer therapi report method use target screen small molecul inhibitor tumor provid approach screen tumor inhibitor natur product
|
D034902;D001688
|
T123;T121;T002
|
36,283,122
|
fuse cycloheptatrien bodipi high perform near infrar probe imag tau tangl neurofibrillari tangl nfts compos abnorm hyperphosphoryl tau one main patholog hallmark alzheim diseas tauopathi fluoresc imag probe current use target nfts distinguish well amyloid plaqu thus limit util diagnos diseas develop fuse cycloheptatrien bodipi deriv tnir display properti favor near infrar nir imag high affin specif nfts vitro addit tnir effect penetr blood brain barrier clear distinguish tauopathi transgen mice rtg control mice use nir fluoresc imag vivo sensit specif tnir nfts confirm ex vivo fluoresc stain tauopathi mous model molecular dock studi indic tnir bound nfts hydrophob interact result suggest tnir act high perform probe detect nfts vitro vivo select
|
D024801;D000544
|
T047;T048
|
36,283,107
|
diverg pathway ammonia urea product excret life cycl sea lamprey littl known nitrogen wast n wast handl excret j n wast complex life cycl sea lamprey petromyzon marinus extant jawless fish undergo complet metamorphosi filter feed larva ammocoet parasit juvenil feed blood larger jaw fish investig ammonia urea handl profil sea lamprey metamorphosi rate ammonia excret j amm urea excret j urea signific decreas onset metamorphosi lowest rate observ midmetamorphosi near complet metamorphosi rate j n wast jn wastejammjurea signific increas sea lamprey enter juvenil period feed juvenil lamprey greater fold higher j amm fivefold higher j urea compar nonf juvenil correspond higher postprandi postfeed concentr plasma ammonia urea rout j amm j urea complet diverg follow metamorphosi larva j amm equal split branchial gill extrabranchi skin plus renal pathway follow metamorphosi ammonia excret via gill nonfeed juvenil lamprey ammonia excret via gill adult sea lamprey urea hand predomin excret via extrabranchi rout lesser extent gill larva nonfeed juvenil adult howev virtual urea excret via urin revers transcript polymeras chain reaction silico analys also indic urea transport encod slca like gene present lamprey branchial express transport modul throughout sea lamprey life histori higher larva steadili decreas adult stage conclud diverg pathway j amm j urea sea lamprey life cycl reflect chang habitat lifestyl diet near complet relianc renal rout j urea adult sea lamprey uniqu among fish may reflect ancestr condit n wast product handl excret earliest vertebr
|
D048428
|
T013
|
36,283,082
|
farewel great doctor extraordinari believ creator qualiti care dr hctor aguirr gas line farewel express dr hctor gerardo aguirr gas excel doctor great expon qualiti medic care patient safeti train servant medic servic instituto mexicano del seguro social imss nobl companion friend man univers ethic valu straight humbl figur activ bold behavior commit serv other
|
D011787;D012943
|
T058;T064;T169
|
36,283,081
|
clinic reason practic aspect allow facilit develop clinic reason compet doctor develop essenti medic practic clinic reason includ aspect relat observ critic think communic skill patient sinc integr previous knowledg doctor diseas medic problem obtain inform clinic aspect patient provid mental process process clinic inform provid patient health profession interrog anamnesi togeth interpret find physic examin appropri complementari test allow elabor set diagnos like effici clinic decis make present work intend address subject simplest way possibl medic teacher take account facilit develop doctor train
|
D002983;D010820
|
T097;T080
|
36,283,080
|
bond natur fe co complex heme protein although carbon monoxid co known bind ferrous heme cytochrom p enzym ps sinc earliest day p research detail natur ferrous co bond remain elus studi employ dispers correct densiti function theori dft calcul dft base theoret analys investig complex co thiolat imidazol ligat heme contain ferric ferrous iron tradit ferrous co bond heme system interpret qualit term donat backdon complementari occupi virtual orbit pair covp analysi yield one orbit pair donat two backdon togeth specif magnitud energet contribut charg transfer effect three orbit pair near energet signific ferrous co complex therefor total backdon effect much greater donat effect contrast donat effect signific ferric co complex less effici backdon natur ferric co ferrous co bond scrutin use general kohn sham energi decomposit analysi gks eda scheme whose result highlight signific various effect enhanc fe co bond thiolat imidazol ligat heme group particular intrins repuls effect play crucial role promot preferenti bind co toward ferrous heme determin geometri complex
|
D006420
|
T123;T116
|
36,283,073
|
syphilit chancr mouth unusu locat case report syphili infecti diseas caus spirochet treponema pallidum transmit main direct contact lesion primari syphili usual present chancr site infect high contagi resolv without treatment aim articl illustr unusu locat syphilit chancr order consid diagnosi within approach patient oral ulcer
|
D013587;D002601;D012871
|
T184;T047
|
36,283,072
|
salt induc dissolut protein aggreg protein aggreg mediat complex interplay noncoval interact associ broad rang aspect debilit human diseas food industri therapeut biotechnolog deciph intric role noncoval interact paramount import design effect inhibitori disaggreg strategi remain formid challeng use combin spectroscop microscop tool show surfact mediat protein aggreg modul intrigu interplay hydrophob electrostat effect addit result illumin uniqu role salt potent disaggreg induc alter protein surfact electrostat interact trigger dissolut preform protein aggreg result restor nativ protein structur unusu salt induc dissolut refold offer uniqu approach regul balanc protein self assembl disassembl offer potent strategi design electrostat target inhibitor
|
D066329;D011506
|
T123;T116
|
36,283,071
|
organocatalyt enantioselect nitrogen disubstitut aldehyd absenc solvent high effici enantioselect nitrogen method disubstitut aldehyd azodicarboxyl promot chiral carbam monoprotect cyclohexa diamin organocatalyst develop process carri without solvent correspond disubstitut nitrogen aldehyd obtain excel yield enantioselect ee sustain procedur establish calcul green metric ecoscal e factor addit theoret calcul use justifi obtain enantioselect sens
|
D000447;D003959
|
T109
|
36,283,069
|
regio stereoselect norrish yang photocycl dialkyl diketon solut versus solid state photochemistri two polymorph shown x ray crystallographi crystal acetoxi seco dioxopregn ene nitril dimorph regioselect norrish yang type ii photocycl visibl light steroid diketon bear primari secondari tertiari nonequival abstract hydrogen dramat increas crystallin state polymorph x ray crystallographi molecular mechan calcul reveal crystal structur solid state photochemistri relationship
|
D007659;D008027
|
T070;T109
|
36,283,065
|
cutan hyperpigment manifest acut chronic liver failur acquir cutan pigment repres littl recogn clinic manifest liver disord acut chronic occur exacerb process preexist hepatopathi context acut chronic liver failur sever hypothes increas pigment skin mucous membran develop tri explain defect degrad melanin secondari accumul tissu other hand describ consequ releas fibroblast growth factor like endotheli growth factor hepatocyt growth factor produc stimul liver regener caus melanogenesi stimul aim articl studi pigmentari skin chang background liver diseas
|
D065290;D017495
|
T047;T046
|
36,283,060
|
gastric pull caustic stenosi present complex clinic case chemic substanc import caus gastrointestin tract injuri usual affect two group patient children year age adult attempt suicid effect rang necrosi perfor digest tract affect mouth pharynx esophagus stomach main complic accident caustic ingest esophag strictur frequenc esophag strictur appear rang relat degre injuri induc ingest agent may becom symptomat second third week latent repair phase case month year ingest differ form treatment appli treat caustic esophag strictur endoscop dilat first line success result patient effect surgic treatment esophag replac indic
|
D002424;D002057;D004940
|
T131;T197;T037;T047
|
36,283,057
|
regul nitric oxid releas membran fluiditi ruthenium nitrosyl complex embed phospholipid vesicl incorpor water insolubl nitric oxid releas molecul biocompat vesicl may allow tunabl control releas specif target site vesicl membran fluiditi play import role influenc final therapeut effici drug load vesicl henc aim investig effect lipid fluiditi releas behavior photo control ruthenium nitrosyl ru complex regard new photoact ruthenium nitrosyl complex lru amphiphil terpyridin ligand synthes character detail lru incorpor commerci phospholipid form nanoscal vesicl lru lip photoact ru type complex releas organ solvent ch cn aqueous liposom solut irradi low intens blue light nm w demonstr effect lipid structur fluiditi releas four differ liposom system lru lip prepar use phospholipid dopc dspc dppc dmpc differ chain length satur releas abil liposom aqueous medium studi uv vis spectrum colorimetr greiss fluoresc daf assay result show rate releas could easili tune vari lipid fluiditi effect temperatur ph releas also studi complex lru liposom lru lip assay antibacteri agent strain bacteria escherichia coli staphylococcus aureus
|
D012428
|
T196
|
36,283,055
|
medic econom certif cost budget health system health system necessari assess cost product servic magnitud budget oper formul histor public budget health complement zero base budget refer medic technic cost econom medic certif group relat diagnosi group relat outpati care imss prepar certif scenario treatment hospit outpati diagnosi four success phase group imss profession certif contain inform cost product servic specifi product function patient transit servic product factor instal capac includ personnel kind depreci general servic medicin medic consum laboratori offic studi specif studi procedur respect unit cost refer technic medic cost provid econom medic certif necessari scale allow estim budget servic care unit institut health system medic epidemiolog technic econom inform
|
D000553;D017048
|
T081;T058;T073;T093
|
36,283,054
|
extens guidelin report type studi medicin use differ guid report type studi medic field wide dissemin decad howev adher use import part research still limit negat impact dissemin new find generat critic regard medic research design conduct report parallel extens guidelin littl known use personnel involv research work focus specif approach report differ type studi among meta analysi systemat review clinic trial random diagnost accuraci studi observ studi among other reason promot knowledg use vital import object review synthes main extens guidelin use medic research purpos main characterist review well applic scenario accord level evid adequ adher allow health personnel involv research work increas transpar qualiti find contempl potenti sourc bias well develop good practic present result accord type studi select
|
D035843;D019317
|
T062;T091
|
36,283,052
|
unsupervis domain adapt extra featur target domain use optim transport domain adapt aim transfer knowledg label instanc obtain sourc domain target domain fill gap domain domain adapt method assum sourc target domain dimension method applic number featur differ domain rare studi especi label inform given test data obtain target domain letter assum common featur exist domain extra new addit featur observ target domain henc dimension target domain higher sourc domain leverag homogen common featur adapt sourc target domain formul optim transport ot problem addit learn bound target domain propos ot base method deriv propos algorithm valid use simul real world data
|
D000465;D007858
|
T062;T170;T041;T061
|
36,283,051
|
total synthes ineleganolid sinulochmodin c describ herein first total synthes furanocembranoid natur product ineleganolid sinulochmodin c synthet strategi predic transannular michael reaction provid natur product common macrocycl intermedi leverag diastereoselect radic cyclize furnish key bicycl lacton latter advanc macrocycl precursor via nozaki hiyama kishi cyclize one pot furan oxidationoxa michael cascad unexpect stereochem nuanc guid evolut eventu complet total synthesi discuss
|
D004224;D001688
|
T123;T121;T109
|
36,283,044
|
asymmetr complex pupil control model later imbalanc neural activ locus coeruleus potenti biomark attent deficithyperact disord locus coeruleus lc overact especi right hemispher recogn pathophysiolog attent deficithyperact disord adhd may relat inattent lc activ synchron kinet pupil diamet reflect neural activ relat cognit function attent arous recent studi highlight import complex tempor pattern pupil diamet moreov asymmetr pupil diamet correl sever inattent impuls hyperact adhd might attribut left right imbal lc activ recent construct comput model pupil diamet base newli discov contralater project lc eding westphal nucleus ewn demonstr mechan complex tempor pattern pupil kinet howev remain unclear lc overact asymmetri affect pupil diamet hypothes neural model pupil diamet control featur left right differ lc activ project onto two oppon side may clarifi role pupil behavior adhd studi therefor develop pupil diamet control model reflect lc overact right hemispher incorpor contralater project lc ewn evalu complex tempor pattern pupil diamet generat model upon comparison experiment measur pupil diamet adult patient adhd paramet region interest neural model estim region two dimension plot complex versus left side lc baselin activ right region result relat high right side complex correspond pathophysiolog index identifi anticip discoveri later complex pupil diamet fluctuat facilit develop biomark accur diagnosi adhd
|
D008125;D001289
|
T023;T048
|
36,283,043
|
memoryless optim neuron need adapt optim encod stimuli arbitrarili complex statist neuron seem capabl handl type data regardless scale statist properti letter suggest optim code may occur singl neuron level without requir memori adapt evolutionari driven fit stimuli refer neural circuit optim maxim mutual inform input output show often encount differenti neuron neuron respond main chang input capabl use inform capac handl sampl statist distribut demonstr optim use analyt method simul addit demonstr simplic eleg neural process result might provid way improv handl data artifici neural network
|
D008959;D009474
|
T170;T025
|
36,283,042
|
larg scale algorithm search identifi stiff sloppi dimens synapt architectur consist murin neocort wire complex system defin sloppi dimens mean behavior unmodifi larg chang specif paramet combin stiff dimens whose chang result consider behavior modif neocortex sloppi synapt architectur would crucial allow mainten asynchron irregular spike dynam low fire rate despit divers input state short long term plastic use simul neural network first order spike statist match fire murin visual cortex vari connect paramet determin stiff sloppi paramet synapt architectur across three class input brief continu cyclic algorithm generat connect paramet valu drawn larg portion paramet space reveal specif combin excitatori inhibitori connect stiff architectur detail sloppi stiff dimens consist across input class self sustain synapt architectur follow brief input occupi smaller subspac compar input class experiment estim connect probabl mous visual cortex consist connect correl found fall region paramet space architectur identifi algorithm suggest simpl statist descript spike dynam suffici parsimoni descript neocort activ examin structur function relationship mesoscop scale addit coars grain cell type prevent generat accur inform interpret model under simpl spike activ unbias investig provid evid import interrelationship excitatori inhibitori connect establish maintain stabl spike dynam regim neocortex
|
D019579;D014793
|
T023;T029;T024
|
36,283,040
|
polici strategi combat obes latin america latin america region highest preval overweight obes therefor strategi polici implement countri reduc health problem among fiscal polici tax sugari drink high calori product regul advertis food label
|
D050177;D013660
|
T033;T081;T064
|
36,283,034
|
epidemiolog clinic characterist covid epidem mexico quintana roo case identifi risk factor sever outcom mexican patient covid popul quintana roo
|
D000086382;D003920;D006973
|
T047;T067
|
36,283,033
|
impact germin brown rice brown rice metabol inflamm gut microbiom high fat diet induc insulin resist mice constitu germin brown rice gbr brown rice brr white rice whr impact metabol inflamm gut microbiota high fat hf diet fed mice examin content total fiber aminobutyr acid brr gbr higher whr p male c blj mice receiv hf diet g whr brr gbr week brr gbr compar reduc hf diet induc increas fast plasma glucos lipid insulin resist inflammatori marker compar whr p abund fecal bacteroidet mice fed hfgbr hfbrr higher hfwhr fed mice p abund fecal lactobacillus gasseri gbr fed mice greater whr brr fed mice p result indic gbr brr attenu hyperglycemia insulin resist inflamm mice hfgbr hfbrr increas probiot bacteria gut
|
D000069196;D012275;D007333
|
T007;T001;T168;T046;T002
|
36,283,027
|
physic inact young peopl home confin due covid physic inact high preval condit world associ increas suscept develop comorbid present sever respiratori distress syndrom due covid
|
D057185;D000086382
|
T033;T047;T079;T067
|
36,283,026
|
epidemiolog clinic characterist survivor sar cov infect descript studi march world health organ declar pandem coronavirus typic symptom fever cough asthenia dyspnea muscl pain pulmonari central nervous system compromis present challeng characterist healthcar physician object studi identifi epidemiolog clinic characterist sar cov infect survivor region argentina determin differ gender age group year infect evolut time sinc diagnosi
|
D000086382;D000370
|
T184;T067;T033;T047;T048
|
36,283,025
|
synthesi evalu prodrug carboxi nucleosid phosphon rang lipophil prodrug carboxi nucleosid phosphon potent inhibitor hiv revers transcriptas without requir prior phosphoryl synthes evalu vivo potenc hiv cell cultur seri prodrug deriv bear free carboxyl acid phosphon mask bispivaloyloxymethyl diisopropyloxycarbonyloxymethyl bisamid aryloxyphosphoramid hexadecyloxypropyl cyclos acycloxybenzyl moieti synthes adapt exist methodolog phosphon protect accommod adjac carboxyl acid moieti prodrug assay anti hiv activ cem cell culturesth bispivaloyloxymethyl free acid monophosphon prodrug exhibit activ inhibitori concentr ic prodrug inact racem bispivaloyloxymethyl methyl ester monophosphon prodrug also prepar assess suitabl methyl ester carboxyl acid prodrug compound exhibit activ hiv cellular assay
|
D063065;D011355;D019380
|
T120;T131;T121;T109
|
36,283,017
|
asept loosen joint prosthes asept observ chang periarticular space may caus mechan action biolog reaction periprosthet infect common caus loosen destruct chang joint howev diagnosi asept reaction alway fulli obvious micromov implant surround bone caus remodel bone trabecula migrat fibroblast void implant surfac bone addit repetit stress induc fibroblast prolifer hand residu aris wear implant materi joint may play import role process loosen prosthes asept septic direct interact releas molecul macrophag surfac suffici activ osteoclastogen signal pathway ignor allerg reaction metal use prosthes patient undergo arthroplasti demonstr hypersensit compon dentur case requir use appropri materi order caus inflammatori allerg reaction emerg treatment strategi use mesenchym stem cell mscs aim improv initi implant integr prevent periprosthet osteolysi emphas howev diagnosi asept loosen mani clinic situat rais doubt root everyon
|
D007595;D010014
|
T074;T046
|
36,283,016
|
nativ heart valv thrombosi associ covid report case nativ heart valv thrombosi nhvt rare valvular patholog usual associ prothrombot state disturb intracardiac blood flow relat structur valv abnorm differ venous arteri thromboembol complic covid wide describ far nhvt report context diseas author describ case nhvt associ covid reveal aortic mitral patient tricuspid valv yearold male mild pneumonia larg thrombus develop bicuspid aortic valv bav result fatal brain emboli yearold male histori rheumatoid arthriti ra recoveri period covid central retin arteri occlus crao first sign mitral valv thrombus disappear week apixaban use therapi also success yearold femal multipl cardiovascular risk factor mitral valv thrombus found routin echocardiographi got covid third time year old man moder covid pneumonia bacteri coinfect coexist transient focal lv dysfunct tricuspid valv thrombus observ patient treat apixaban well howev case reduct thrombus size seen month therapi author indic patient covid nhvt prothrombot condit usual found complic may involv differ valv occur irrespect covid sever interdisciplinari evalu patient necessari
|
D000086382;D006331;D003328
|
T047;T067
|
36,283,015
|
diagnost difficulti igg relat diseas case report igg relat diseas belong group immun mediat diseas relat new condit classifi character involv multipl organ time caus organ failur observ radiolog chang slow grow rule cours diseas subclin mean diagnosi often made incident retrospect mani year onset symptom initi stage diagnosi often confus sjgren syndrom system vascul neoplast disord
|
D000077733;D056647
|
T033;T047
|
36,283,014
|
efficaci rituximab minim chang diseas atyp renal manifest antiphospholipid syndrom antiphospholipid syndrom ap defin presenc antiphospholipid antibodi along hypercoagul event renal involv ap usual manifest thromboembol complic observ larg blood vessel small intraren vessel ap nephropathi report rare case glomerul associ ap characteris featur differ typic ap nephropathi
|
D016736;D009402;D009404;D007674
|
T047
|
36,283,013
|
nephrolog urolog symptom patient robinow syndrom report two case robinow syndrom rare congenit syndrom describ meinhard robinow genet background heterogen mutat dvli dvli wnta gene mild autosom domin inherit ror gene sever autosom recess inherit respons syndrom syndrom character facial dysmorph skelet defect short statur cardiovascular urinari system abnorm
|
D014718;D009398;D017880;D004392
|
T019;T047;T091
|
36,283,012
|
implant av leadless pacemak case report earli food drug administr fda approv micra av new type leadless pacemak atrioventricular synchroni treat patient atrio ventricular av block describ one first poland case patient implant micra av pacemak
|
D054537;D010138;D004696
|
T047;T074
|
36,283,011
|
current therapeut option treatment secondari hyperparathyroid end stage renal diseas patient treat hemodialysi month compar studi aim studi investig effect new calcimimet etelcalcetid secondari hyperparathyroid effect end stage renal diseas esrd patient treat hemodialysi hd compar hemodialysi hd patient treat calcimimet
|
D006962;D007676
|
T047
|
36,283,010
|
respiratori microbiota good predictor outcom humor immunodefici methodolog conceptu difficulti comprehens microbiom analysi microbiom broad term defin dynam ecolog system apart biocenosi uniqu nich develop equal dynam host deriv contrari physic environ ecolog although year antibodi recogn key element mucos barrier still progress comprehens link microb humor element organ pathogen commens still exact answer criteria also discrep experiment research use sophist techniqu show exist near bacteri speci mouth observ contrari bacteri infect caus novel speci recognis patient humor immunodefici apart capsular cocci h influenza research human virom includ cmv also focus cellular immun mani situat clinic humor compart exclus still effect barrier viral replic
|
D064307;D000069196
|
T001;T032;T028;T007
|
36,283,009
|
warto prognostyczna wskanikw elektrokardiograficznych zawau prawej komori w oceni wewntrzszpitalnego przebiegu klinicznego u chorych z rozpoznanym zawaem ciani dolnej leczonych interwencyjni myocardi infarct mi right ventricl rv coexist patient inferior mi electrocardiograph indic connect rv mi may also predict unfavor clinic outcom hospit follow
|
D054537;D000072657;D009203
|
T047
|
36,283,008
|
role serotonin pathogenesi unclassifi irrit bowel syndrom pathogenesi irrit bowel syndrom ib clear understood numer factor includ neurotransmitt interfer function digest tract
|
D043183;D008550
|
T125;T121;T047;T109
|
36,283,007
|
cytolog transform cervix immunodefici aggrav alcohol comorbid patholog high mortal disabl remain urgent problem peopl develop immunodefici state includ women reproduct age prognost trigger could help improv manag preneoplast injuri cervic epithelium
|
D015658;D000437;D002583
|
T047;T191;T048
|
36,282,995
|
delta neutrophil lymphocyt index mortal covid diseas acut respiratori distress syndrom due sar cov worldwid health problem neutrophil lymphocyt index allow risk stratif patient sever poor prognost data sinc reflect inflammatori state
|
D000086382;D012128
|
T047;T067
|
36,282,994
|
activ two photon near infrar ratiometr fluoresc nanoprob onoo detect earli diagnosi assess liver injuri liver injuri pose serious threat human health grow evid suggest close associ biomark peroxynitrit onoo therefor consid relationship onoo level occurr develop liver injuri diseas remain challeng urgent need exist develop reliabl robust tool visual rapid diagnosi assess herein two photon near infrar tp nir ratiometr fluoresc nanoprob ntc base fluoresc reson energi transfer fret strategi design synthes character advantag good water solubl low background interfer deep tissu penetr high imag resolut special ntc construct self assembl alkynyl group small molecul fluoresc probe nr via click chemistri graft onto azid chitosan natur polymer nanomateri nr contain acceptor nir fluorophor donor structur naphthalimid deriv fluorophor outstand tp properti could activ onoo ratiometr detect onoo furthermor presenc onoo ntc exhibit short respons time high select sensit toward onoo excel detect limit low nm reactiv oxygennitrogen speci notabl ntc success employ onoo detect imag live hepg cell liver injuri mice tissu mice model satisfactori result thus construct ntc nanoprob provid robust molecul tool enabl earli diagnosi assess liver injuri futur
|
D030421;D005456
|
T123;T197;T130
|
36,282,989
|
base trisubstitut alken environment sensit fluoresc probe detect lewi patholog lewi patholog main consist insolubl synuclein syn aggreg hallmark parkinson diseas mani neurodegen diseas term synucleinopathi detect lewi patholog optic method interest preclin studi syn fluoresc probe still great demand ration design obtain seri base trisubstitut alken accept optic properti high bind affin syn fibril among probe fpqxn tqxn exhibit high bind affin nm respect signific fluoresc enhanc fold respect satisfi quantum yield respect met need vitro neuropatholog stain lewi patholog pd brain section addit tqxn show great potenti fluoresc discrimin lewi patholog plaqu research provid flexibl tool vitro detect syn aggreg offer new structur framework develop syn fluoresc probe
|
D005456;D010300
|
T047;T130
|
36,282,987
|
etiolog bacteri pneumonia patient covid aggreg bacteri pneumonia play fundament role mortal patient hospit covid
|
D000086382;D018410
|
T047;T067
|
36,282,974
|
socio labor condit psycholog burnout worker pandem compar studi pandem deriv covid caus great impact context wich human oper includ labor context multipl studi shown influenc covid pandem public privat organ deriv import assess real work context mexican popul time pandem factor relat appear psycholog exhaust
|
D000086382;D002055
|
T047;T067;T048
|
36,282,961
|
molecular inform theori meet protein fold propos applic molecular inform theori analyz fold singl domain protein analyz result various area protein scienc sequenc base potenti reduc amino acid alphabet backbon configur entropi secondari structur content residu burial layer mutat studi protein stabil chang found averag inform contain sequenc evolv protein close averag inform need specifi fold bit siteoper effect alphabet size evolv protein equal effect number conform residu compact unfold state around calcul energi inform convers effici upon fold around lower theoret limit much higher human built macroscop machin propos simpl map molecular inform theori energi landscap theori explor connect sequenc evolut configur entropi energet protein fold
|
D007257;D017510
|
T090;T044
|
36,282,958
|
valor wast tungsten filament mpg c n wo photocatalyst sustain e wast manag wastewat treatment wast tungsten filament materi environ one reason environment pollut danger anim plant date much attent given util recycl herein present work report synthesi tungsten trioxid nanoparticl wo nps util cost free wast tungsten filament simpl calcin method mesopor graphit carbon nitrid tungsten trioxid mpg c n wo composit design wo nps produc tungsten filament wast thiourea carbon nitrogen precursor one step calcin method synthes sampl character confirm differ character techniqu photocatalyt behavior synthes mpg c n wo composit assess respect effect initi ph amount photocatalyst dye concentr reaction time well degrad methylen blue mb dye sunlight best photocatalyt perform achiev use mpg c n wo experiment condit photocatalyst mgl mb mgl ph time min sunlight irradi excel photost isol mpg c n wo nps histotoxicolog studi also show photodegrad product mb found nontox structur chang gill architectur well brain tissu freshwat fish labeo rohita
|
D059029;D018508
|
T068;T052;T057
|
36,282,957
|
simpl blood vessel imag protocol live zebrafish larva zebrafish larva simpl model system studi blood vessel develop excel optic properti current method studi blood vessel zebrafish involv util either blood vessel specif transgen line special techniqu microangiographi video capillaroscopi studi develop simpl protocol use imagej observ blood vessel live zebrafish larva differ development stage name day postfertil dpf valid protocol treat dpf zebrafish embryo quercetin analyz impair develop subintestin vein quercetin treat dpf larva
|
D015027;D011794
|
T121;T109;T127;T013
|
36,282,955
|
acetonitril ligand photosubstitut ru ii complex direct mlct state excit state seri ru tpi l ch cn n n contain bident ligand l vari electron donat abil character arrhenius analysi temperatur depend excit state lifetim complex undergo photoinduc ch cn dissoci upon nm irradi ligand exchang quantum yield increas energi barrier popul dissoci triplet ligand field lf state lowest energi triplet metal ligand charg transfer mlct excit state combin dft calcul data indic ligand photodissoci occur direct mlct state instead lf state find contrast general accept mechan ligand photodissoci ru ii complex indic altern pathway photoinduc ligand dissoci avail result wide impact design principl applic requir ligand photodissoci photochemotherapi photocatalysi well photosubstitut undesir solar energi convers
|
D012428
|
T196
|
36,282,953
|
sodium isopropyl trimethylsilyl amid stabl high solubl lithium diisopropylamid mimic prepar structur physic properti reactiv sodium isopropyl trimethylsilyl amid napta describ solubl room temperatur rang n heptan n hexan toluen mtbe et n thf half life destruct neat thf year c day c compar favor month day respect lda neat thf studi focus napta thf si nmr spectroscopi show exclus mixtur cis tran stereoisomer dimer thf hexan densiti function theori dft comput suggest p k b intermedi dimer sodium diisopropylamid nada dimer sodium hexamethyldisilazid nahmd metal aren epoxid keton hydrazon alken alkyl halid show higher reactiv lda k naptalda rate aren metal high lower p k b napta limit substrat metal pseudoephedr base carboxamid form disodi myer enol solv sever challeng technic problem
|
D012964;D000577
|
T123;T196;T034;T109
|
36,282,945
|
reduct rare earth metal complex induc irradi util irradi generat unstabl low oxid state molecular speci contain rare earth metal ion frozen solut examin method evalu irradi ln iii precursor ln sc la solid matrix methyltetrahydrofuran k kev cs sourc generat free electron capabl reduc ln iii speci experi yield epr uv visibl spectroscop data match known ln ii speci c h sime ii c h sime la ii sc ii n sime irradi la iii complex la iii n sime method gave epr uv visibl absorpt spectra consist la ii n sime speci previous elud prepar chemic reduct specif irradi product exhibit axial epr spectrum split eight line la nucleus g g ave g uv visibl absorpt spectrum contain broad band center nm consist la ii ion trigon ligand environ base time depend densiti function theori qualit reproduc observ spectrum addit rate format c h sime ii speci irradi c h sime iii monitor measur concentr via uv visibl spectroscopi time provid data rate molecular speci reduc glass via irradi
|
D056831;D008674
|
T104;T196
|
36,282,937
|
health care resourc util cost among individu vs without huntington diseas us popul background quantifi extent health care resourc util hcru cost associ huntington diseas hd vital provid decisionmak payer understand unmet treatment need ensur limit resourc use benefit maximum number peopl hd object quantifi hcru cost peopl hd overal diseas stage compar non hd control method retrospect cohort studi use administr claim data ibm marketscan commerci multi state medicaid medicar supplement databas januari decemb peopl hd claim januari decemb select analysi match non hd control comparison hd cohort non hd control exact match follow durat propens score match creat final analyt cohort index date first hd diagnosi hd cohort proxi index date assign control individu requir continu enrol month pre index baselin month post index proport caus hcru ie outpati visit inpati visit emerg depart visit pharmaci fill radiolog visit physicaloccup therapi visit month post index hcru count cost per patient per month pppm entir follow calcul cohort result total individu hd match non hd control identifi hcru month post index signific greater peopl hd compar non hd control health care servic categori p mean number hcru pppm measur healthcar servic signific higher peopl hd compar non hd control p mean total cost usd pppm hd cohort sd twice total cost non hd cohort sd p highest across diseas stage conclus studi provid current comprehens hcru cost estim individu hd relat without diseas thus demonstr high econom burden impos hd disclosur dr ta employ genentech time studi stock option roch dr employ stock optionsdividend genentech dr patel employ stock option rochegenentech dr fuller employ chdi managementchdi foundat mr surinach employ genesi research receiv consult fee genentechroch dr abbass employ stock option genentech dr exuzid employ stock option rochegenentech ms luo employ chdi managementchdi foundat studi fund genentech inc author thank greg row chrysali medic communic provid medic write support fund f hoffmann la roch ltd accord good public practic gpp guidelin http wwwismpporggpp
|
D017048;D006816
|
T081;T047
|
36,282,935
|
comparison real world clinic econom outcom patient receiv oral anticoagul retrospect claim analysi background direct oral anticoagul doac becom wide use prevent stroke nonvalvular atrial fibril af treatment venous thromboembol vte warfarin standard care prior doac requir monitor dose adjust ensur patient remain appropri anticoagul doac requir monitor signific expens sought examin real world effect cost doac warfarin patient af vte object examin clinic econom outcom clinic object determin bleed thrombot event rate associ doac vs warfarin econom object determin cost associ event well caus medic pharmaci cost associ doac vs warfarin method analysi observ propens match comparison retrospect medic pharmaci claim data member enrol integr health plan octob septemb member older year age least day suppli warfarin doac fill within day new diagnosi vte nonvalvular af elig analysi cox hazard ratio use compar differ clinic outcom pair test use evalu econom outcom result match patient group among match member warfarin associ increas risk nonmajor bleed relat apixaban hazard ratio hr p increas risk pulmonari embol relat doac apixaban hr p rivaroxaban hr p statist signific differ observ hospit length stay warfarin either doac differ differ total cost care per member per month apixaban rivaroxaban relat warfarin p p respect vte relat cost apixaban less relat warfarin p caus pharmaci cost apixaban rivaroxaban relat warfarin p p respect conclus warfarin use associ signific decreas total cost care despit signific increas vte relat cost vs apixaban warfarin also associ signific increas nonmajor bleed relat apixaban well signific increas pulmonari embol relat doac warfarin associ signific reduct caus pharmaci cost compar either doac disclosur author studi noth disclos
|
D054556;D001281;D020521;D011655
|
T047;T046
|
36,282,934
|
trend endpoint use pivot trial efficaci us food drug administr approv solid tumor therapi background mani cancer therapi approv base surrog endpoint progress free surviv pfs ensur patient speedi access life save cancer medicin howev link surrog endpoint overal surviv os well establish mani cancer object character trend endpoint use pivot trial lead approv us food drug administr fda approv solid tumor therapi efficaci method review fda oncolog cancer hematolog malign approv notif webpag extract data median os pfs among solid tumor therapi approv summar trend percentag trial report os vs pfs median os pfs trial design conduct subgroup analys lung breast cancer therapi result median os report frequent median pfs os report trial respect observ trend median os time solid tumor therapi approv median pfs increas month time lung cancer therapi median os increas month time period wherea median pfs increas month time period breast cancer therapi median os slight decreas time wherea median pfs increas month sinc recent shift use singl arm trial lead oncolog drug approv conclus transit report os pfs median pfs increas month median os remain stabl differ trend overal progress free surviv highlight challeng import measur valu oncolog drug disclosur dr suh report person fee bayer us llc
|
D008175;D001943
|
T191
|
36,282,933
|
ad ribociclib fulvestr cost effect treat postmenopaus women hrher advanc metastat breast cancer us payer perspect cost util analysi background breast cancer preval type cancer women unit state ribociclib plus fulvestr combin therapi gain us food drug administr approv treat postmenopaus women hormon receptor positivehuman epiderm growth factor receptor negat hrher advanc metastat breast cancer object determin cost effect ribociclib plus fulvestr vs placebo plus fulvestr therapi target popul us payer perspect method partit surviv analysi model compos health state progress free progress diseas death construct evalu cost effect ribociclib plus fulvestr vs placebo plus fulvestr progress free surviv overal surviv data point extract publish kaplan meier curv monaleesa studi fit parametr curv safeti efficaci treatment referenc monaleesa trial cost obtain standard sourc includ red book medic cost medicar clinic laboratoryphysician fee schedul clinic util literatur cost manag advers event subsequ therapi end life care util disutil valu obtain literatur calcul qualiti adjust life year qali one way probabilist sensit analys conduct test model robust sever scenario analys also investig result base case ribociclib plus fulvestr arm associ qali compar qali placebo plus fulvestr arm lead increment cost effect ratio qali cost ribociclib biggest impact model constitut total cost ribociclib plus fulvestr arm probabilist sensit analysi project ribociclib plus fulvestr treatment would net benefit placebo plus fulvestr therapi willing pay wtp threshold qali conclus wtp threshold qali addit ribociclib fulvestr consid cost effect postmenopaus women hrher advanc metastat breast cancer find send strong price signal manufactur use facilit payer price negoti make coverag decis
|
D001943
|
T191
|
36,282,932
|
health care cost util prior diagnosi antineutrophil cytoplasm antibodi vascul medicar beneficiari background antineutrophil cytoplasm antibodi anca vascul av complex group autoimmun disord affect blood vessel multipl organ system delay diagnosi common av symptom nonspecif present heterogen may result increas health care util month preced diagnosi object examin whether medicar beneficiari av experienc increas health care util cost year first diagnosi record claim relat beneficiari without av method retrospect cohort studi use medicar part ab claim part prescript drug data beneficiari newli diagnos av identifi inpati claim noninpati claim day apart intern classif diseas tenth revis clinic modif code av av claim year prior beneficiari av match age sex beneficiari without diagnos type system vascul beneficiari part ab coverag ab n part abd coverag abd n analyz separ estim general linear mix model negat binomi distribut compar health care cost util av status result beneficiari av approxim time higher medicar part ab payment incid rate ratio ci ab abd time higher beneficiari part ab payment ab abd vs beneficiari without av beneficiari av experienc signific higher util across categori largest differ observ hospit outpati visit ab abd conclus year prior av diagnosi medicar beneficiari signific higher health care cost util beneficiari without av disclosur dr huang support univers north carolina glaxosmithklin health outcom fellowship time studi report current employ horizon therapeut deerfield il dr nguyen receiv predoctor fund fellowship appoint sponsor bristol myer squibb time studi report current employ glaxosmithklin collegevill pa dr derebail receiv person fee traver therapeut bayer uptod outsid submit work view express author repres view depart veteran affair research receiv specif grant fund agenc public commerci profit sector
|
D055553;D014657
|
T121;T047
|
36,282,931
|
within trial econom analysi resourc use comet ice phase clinic trial evalu sotrovimab treatment patient covid high risk progress background final result primari endpoint covid monoclon antibodi efficaci trial intent care earli comet ice random control trial nct show p adjust relat risk reduct longer hour hospit death due caus high risk patient covid receiv sotrovimab compar placebo day given substanti cost associ covid hospit need quantifi econom impact clinic trial outcom inform decisionmak object compar longer hour hospit cost primari object total health care cost secondari object associ covid care sotrovimab vs placebo group comet ice trial method step retrospect post hoc within trial econom analysi step health care claim marketscan databas analysi sourc unit cost data usd us payer perspect covid care relat resourc use april june among adult diagnos covid high risk progress similar enrol comet ice trial cost per day inpati event stratifi follow maximum respiratori support level obtain respiratori support oxygen therapi noninvas ventil invas mechan ventil cost per event obtain outpati resourc use step within trial econom analysi unit cost step appli resourc use base maximum respiratori support length stay inpati event number visit outpati event observ first day post random comet ice result total patient intent treat comet ice popul includ sotrovimab n placebo n baselin demograph clinic characterist well balanc group day follow mean sd cost primari endpoint longer hour hospit placebo group sotrovimab group differ p total health care cost placebo group sotrovimab group differ p conclus post hoc within trial econom analysi comet ice data show earli treatment sotrovimab vs placebo may associ lower longer hour hospit cost total health care cost covid care high risk patient covid find may import inform decis make regard use sotrovimab clinic practic disclosur dr lokhandwala ms farrelli employe xcenda llc xcenda receiv fund gsk support conduct studi receiv fund manuscript develop mr acharya dr coutinho employe xcenda llc conduct studi mr bell dr svedsat employe hold stocksshar gsk studi fund gsk studi vir biotechnolog inc studi sponsor involv studi design collect analysi interpret data write report decis submit report public
|
D000086382
|
T047;T067
|
36,282,930
|
real world opioid use among patient migrain enrol us commerci insur risk factor associ migrain progress background migraineur may categor episod migrain em mmeday month follow period higher opioid dosag found patient cm comorbid interest compar patient em patient cm twice like receiv least mmeday cm vs em higher median opioid day suppli cm vs em follow patient cm least opioid prescript least mmeday day period follow signific associ found mme level likelihood new onset cm addit signific risk factor migrain progress includ younger age femal sex south west region diagnosi medic overus headach depress back pain fibromyalgia p conclus despit guidelin avail migrain specif treatment opioid still common prescrib patient migrain real world practic especi cm studi popul higher risk new onset cm associ receiv higher opioid dose
|
D009293;D008881;D007341
|
T078;T047;T081;T048
|
36,282,929
|
trend add medic follow metformin monotherapi type diabet background although metformin general univers recommend first line pharmacolog therapi peopl live type diabet second line third line choic requir tailor approach achiev optim blood glucos glycat hemoglobin level object examin nation trend second third line antihyperglycem medic follow metformin monotherapi compar method retrospect cohort analysi deidentifi pharmaci claim larg nation pharmaci benefit manag januari decemb januari decemb includ adult age year continu enrol commerci medicar insur plan fill index metformin prescript either year proport patient second line third line antihyperglycem class calcul result second line use sulfonylurea p combin drug p dipeptidyl peptidas inhibitor p signific declin wherea second line use sodium glucos cotransport inhibitor sgltis p glucagon like peptid receptor agonist glp ras p signific increas similar third line use sulfonylurea declin p wherea third line use sgltis p glp ras p increas similar trend found commerci medicar subgroup among group compar sulfonylurea prescrib second line class insulin common third line class although sglti glp ra togeth repres one third second line third line prescript commerci insur patient respect class less frequent prescrib medicar subgroup respect conclus report provid updat second line third line antihyperglycem medic prescrib trend unit state suggest evid base guidelin use practic prevent complic individu diabet care disclosur ms swart drs peasah good employ upmc health plan dr neilson employ upmc health plan time studi drs munshi henderson employ evernorth time studi
|
D008687;D003924;D054873
|
T121;T047;T109
|
36,282,928
|
specialti pharmaci turnaround time impedi facilit good practic background patient receiv specialti medic condit often complex high cost high need prompt treatment initi essenti appropri manag mani condit treat specialti product improv turnaround time tat specialti pharmaci prescript help ensur patient receiv medic need necessari time frame optim health outcom despit clinic justif improv tat gap literatur describ factor impact time object determin factor may influenc specialti pharmaci tat identifi good practic specialti pharmaci use improv tat method qualit studi use focus group specialti pharmaci subject matter expert focus group repres differ specialti pharmaci type includ health system payer associ retail chain independ specialti pharmaci attitud belief experi regard specialti pharmaci tat captur open end question prompt elicit impedi facilit good practic associ specialti pharmaci tat ask particip data analyz themat result fifteen individu particip across focus group payer associ n independ n health system n retail chain n specialti pharmaci averag tat vari across specialti pharmaci type prescript type clean vs intervent sever interconnect theme identifi includ barrier health benefit formulari manag prior author delay differ requir manag care organ miscommun physician among other five subthem identifi discuss factor influenc tat includ patient characterist pharmaci characterist provid characterist clinic situat health benefit design formulari consider pharmaci workflow improv technolog integr thought improv tat addit particip note facilit includ special among pharmacist technician certain diseas particular hepat c cancer good practic includ use patient financi advoc technolog integr structur patient onboard process found minim delay caus prior author communic formulari conclus multitud factor impact specialti pharmaci prescript tat identifi multidisciplinari coordin pharmaci physician manag care organ essenti ensur patient receiv medic necessari time frame optim health outcom disclosur studi conduct support pfizer
|
D010594;D010593;D010604;D008511
|
T091;T073;T093;T170;T058;T057
|
36,282,927
|
drug super spender tsunami integr medic pharmaci benefit assess background new rare diseas drug therapi gene therapi high price cancer drug receiv us food drug administr approv increas potenti drug super spender individu annual drug cost object categor member larg commerci insur popul total annual combin drug cost medic pharmaci benefit determin trend drug super spender preval method use commerci insur popul integr medic pharmaci benefit uniqu member enrol januari decemb identifi sum total cost pharmaci claim plus medic benefit claim line drug determin member calendar year cost defin plan plus member liabil network discount price adjust coupon rebat descript statist use describ drug super spender growth result averag million member per year least month elig year studi period total member drug cost per member account million drug spend super spender member increas account million drug cost increas million total drug spend conclus larg commerci insur popul small per number drug super spender member compris disproportion portion total drug expenditur everi dollar total drug expenditur health plan need understand drug super spender trend develop strategi maintain health care afford disclosur studi fund intern prime therapeut llc drs starner gleason employe prime therapeut llc pharmaci benefit manag compani dr bowen former employe prime therapeut llc
|
D000970;D010604
|
T121;T091;T057;T109
|
36,282,926
|
health care resourc util cost associ atrial fibril rural urban dispar background atrial fibril af impos substanti health care econom burden health care system patient previous studi fail examin health care resourc util hcru cost among patient incid af potenti dispar regard geograph locat object examin hcru cost among patient incid af compar patient without af examin whether geograph dispar exist method retrospect cohort studi select patient af patient without af ibmwatson marketscan research databas hcru cost collect month follow af index date use part model bootstrap obtain margin estim cis rural status identifi base metropolitan statist area adjust age sex plan type us region comorbid result among patient af patient without af patient af ci outpati visit ci emerg depart ed visit ci inpati admiss ci higher total cost compar patient without af among patient af rural patient fewer ci outpati visit ci ed visit urban patient overal rural patient af decreas total cost compar urban patient mean ci conclus incid af associ substanti burden health care resourc econom burden burden equal distribut across patient urban vs rural set disclosur dr hansen report grant nation scienc foundat conduct studi
|
D001281
|
T047;T046
|
36,282,925
|
covid adher biolog therapi psoriasi analysi nationwid pharmaci claim data background earli onset covid pandem concern rais use psoriasi treatment particular biolog therapi immunosuppress effect could associ poor prognosi case covid infect object examin chang adher systemat biolog therapi psoriasi onset covid pandem method use iqvia medic pharmaci claim data januari octob identifi patient age year older diagnosi plaqu psoriasi receiv system biolog therapi psoriasi includ provid administ pharmaci dispens therapi calcul incid day gap without therapi per studi particip day interv construct interrupt time seri analys test chang incid outcom pandem declar result sampl includ studi particip femal age year older patient use biolog therapi dispens pharmaci decreas incid day gap without biolog therapi immedi pandem declar gap per patient gap per patient decreas statist signific howev patient use provid administ therapi incid day gap without biolog therapi increas pandem declar gap per patient gap per patient p conclus follow onset covid pandem found increas incid gap biolog therapi psoriasi among user provid administ treatment among user pharmaci dispens therapi disclosur dr hernandez report person fee bristol myer squibb person fee pfizer outsid submit work dr hernandez fund nation heart lung blood institut grant khl funder role design conduct studi collect manag analysi interpret data prepar review approv manuscript decis submit manuscript public statement find conclus view opinion express public base data obtain licens iqvia part iqvia institut human data scienc research collabor
|
D000086382;D011565;D010604
|
T047;T091;T067;T057
|
36,282,923
|
solid phase base synthesi lactazol like thiopeptid strategi synthesi de novo discov lactazol like thiopeptid report approach revolv around converg scalabl prepar central triheterocycl amino acid util fmoc solid phase peptid synthesi modular peptid chain assembl techniqu prepar c termin function thiopeptid biolog studi also describ synthes tnik inhibitor thiopeptid deriv multimilligram quantiti highlight practic util develop protocol
|
D060327;D010455
|
T121;T116;T052;T059
|
36,282,922
|
de novo discoveri thiopeptid pseudo natur product act potent select tnik kinas inhibitor bioengin ribosom synthes post translate modifi peptid ripp emerg approach explor divers pseudo natur product structur drug discoveri purpos howev despit initi advanc area bioactiv reprogram multienzym ripp biosynthet pathway remain major challeng report platform de novo discoveri function thiopeptid base reengin biosynthesi lactazol ripp natur product assembl five biosynthet enzym platform combin vitro biosynthesi lactazol like thiopeptid mrna display prepar screen larg combinatori librari pseudo natur product demonstr util develop protocol affin select traf nck interact kinas tnik protein involv sever cancer yield plethora candid thiopeptid synthes compound high affin target kinas best k nm inhibit enzymat activ best k nm x ray structur analysi tnikthiopeptid interact reveal uniqu mode substrat competit inhibit exhibit two discov compound thiopeptid intern cytosol hekh cell effici known cell penetr peptid tat accord potent compound tp inhibit tnik hct cell altogeth platform enabl explor pseudo natur thiopeptid favor pharmacolog properti drug discoveri applic
|
D001688
|
T123;T121
|
36,282,921
|
phosphoryl rxr mediat effect jnk suppress hepat fgf express promot metabol syndrom cjun nh termin kinas jnk signal pathway liver promot system chang metabol regul peroxisom prolifer activ receptor ppar depend express hepatokin fibroblast growth factor fgf hepatocyt specif gene ablat studi demonstr mapk gene encod jnk play key mechanist role mutual exclus inclus exon b yield express isoform jnk jnk demonstr fgf gene express metabol regul primarili regul jnk isoform identifi relev substrat jnk perform quantit phosphoproteom studi liver isol control mice mice jnk defici hepatocyt mice express jnk jnk hepatocyt identifi jnk substrat retinoid x receptor rxr protein exhibit jnk promot phosphoryl vivo rxr function heterodimer partner ppar may therefor mediat effect jnk signal fgf express test hypothesi establish mice hepatocyt specif express wild type mutat rxr protein found rxr phosphoryl site ser requir suppress fgf gene express collect data establish jnk mediat signal pathway regul hepat fgf express
|
D024821;D047493
|
T047;T116;T192
|
36,282,920
|
coordin expertis foster legal textual cross cultur survey experi reveal domin tendenc reli rule letter spirit decid behavior violat rule tendenc vari mark across k countri owe variat impact moral apprais judgment rule violat compar laypeopl legal expert inclin disregard moral evalu act altogeth consequ exhibit stronger textualist tendenc final evalu plausibl mechan emerg textual two player coordin game incent coordin absenc communic reinforc particip adher rule liter mean togeth studi total n help clarifi origin allur textual especi law within heterogen communiti member diverg moral apprais involv rule purpos rule liter mean provid clear focal point identifi point agreement enabl coordin interpret among citizen lawmak judg
|
D009014;D007600
|
T078;T041
|
36,282,919
|
morpholog growth dynam mechan stabil activ microtubul mechan under spindl self organ spindl dynam intracellular structur self organ microtubul microtubul associ protein spindl bipolar morpholog essenti faith segreg chromosom cell divis robust maintain multifacet mechan howev abnorm shape spindl multipolar spindl stochast aris cell popul caus chromosom segreg error physic basi microtubul fail bipolar occasion favor nonbipolar assembl poor understood use live fluoresc imag quantit shape analysi xenopus egg extract find spindl vari shape morpholog emerg nonrandom bistabl self organ path one lead bipolar lead multipolar phenotyp bistabl defin spindl uniqu morpholog growth dynam link shape phenotyp promot local distort microtubul flow aris within prematur structur also find bipolar multipolar spindl stabl steadi state bulk infrequ switch two phenotyp microneedl base physic manipul demonstr transient forc perturb appli near assembl pole trigger phenotyp switch reveal mechan plastic spindl togeth molecular perturb kinesin augmin data propos physic molecular base under emerg spindl shape variat influenc chromosom segreg fidel cell divis
|
D016547;D008941
|
T026;T123;T126;T116
|
36,282,918
|
childhood hemispherectomi one hemispher support suboptim word face recognit right left cerebr hemispher import face word recognit respect special emerg human develop question whether bilater distribut necessari whether singl hemispher left right support face word recognit face word recognit accuraci patient median age singl hemispher follow childhood hemispherectomi compar match typic control experi particip view stimuli central vision across face word task accuraci left right hemispherectomi patient signific lower control accuraci averag differ compar patient singl hemispher direct one hemispher control experi particip view stimuli one visual field constrain initi process chiefli singl contralater hemispher wherea control higher word accuraci word present right left visual field fieldhemispher differ face contrast left right hemispherectomi patient show compar perform one anoth face word recognit albeit signific lower control altogeth find indic singl develop hemispher either left right may suffici plastic compar represent face word howev perhap due increas competit neural crowd constrain cortic represent one hemispher may collect hamper face word recognit relat observ typic develop two hemispher
|
D038421;D000066499
|
T061;T041
|
36,282,917
|
swap sfps rrc splice factor complex modul pre mrna splice promot photomorphogenesi arabidopsi light signal perceiv group photoreceptor profound effect physiolog growth develop plant redfar red light absorb phytochrom phys modul aspect intric regul gene express multipl level report identif function character rna bind splice factor swap suppressor white apricotsurp rna bind domain contain protein loss function swap mutant hyposensit red light exhibit day length independ earli flower phenotyp swap physic interact two splice factor sfps splice factor phytochrom signal rrc reduc red light respons crycri background light independ manner form ternari complex addit swap physic interact photoactiv phyb coloc nuclear phyb photobodi phenotyp analys show swapsfp swaprrc sfpsrrc doubl mutant display hypocotyl length similar respect singl mutant red light suggest function genet pathway swapsfp doubl swapsfpsrrc tripl mutant display pleiotrop phenotyp includ steril adult stage deep rna sequenc rna seq analys show swap regul gene express pre messeng rna mrna altern splice larg number gene includ involv plant respons light signal compar analysi altern splice among singl doubl tripl mutant show three splice factor coordin regul altern splice subset gene studi uncov function splice factor modul light regul altern splice interact photoactiv phyb splice factor
|
D017360;D029681;D010834
|
T123;T116;T002
|
36,282,916
|
adar regul apol via rna edit inhibit mda activ paradox biolog circuit apol risk variant associ increas risk kidney diseas patient african ancestri individu apol high risk genotyp develop kidney diseas apol gene express correl close degre kidney cell injuri cell anim model mechan regul apol express may critic determin risk allel penetr apol messeng rna includ alu element untransl region form doubl strand rna structur alu dsrna suscept posttranscript adenosin deaminas act rna adar mediat adenosin inosin edit potenti impact gene express studi effect adar express edit apol level podocyt human kidney tissu transgen apol mous model interferon ifn stimul human podocyt adar regul apol prevent melanoma differenti associ protein mda recognit dsrna subsequ type interferon ifn respons knockdown experi show recognit apol messeng rna import contributor mda driven ifn respons mathemat model suggest ifn adar apol network function incoher feed forward loop biolog circuit capabl generat fast transient respons stimuli glomeruli human kidney biopsi exhibit widespread edit apol alu dsrna transgen mous model close replic edit site human apol express mice invers correl adar express ifn stimuli support idea adar regul apol level vivo adar mediat edit import regul apol express could impact penetr sever apol associ kidney diseas
|
D000243;D007370
|
T129;T121;T126;T116
|
36,282,915
|
loss repressor rest affect progesteron receptor function promot uterin leiomyoma pathogenesi uterin leiomyoma ul benign tumor aris myometri layer uterus standard treatment option ul hysterectomi although hormon therapi select progesteron receptor modul often use temporari treatment option reduc symptom slow growth tumor howev sinc pathogenesi ul poor understood hormon therapi base ul specif diverg hormon signal pathway hallmark predict long term efficaci safeti pharmacotherapi remain larg undefin previous studi report aberr express repressor element silenc transcript factorneuron restrict silenc factor restnrsf target gene activ ul growth due near ubiquit loss rest show ablat rest gene mous uterus lead ul phenotyp gene express pattern analog ul includ alter estrogen progesteron signal pathway demonstr mani gene dysregul ul harbor cis regulatori element bound rest progesteron receptor pgr adjac crucial identifi interact rest pgr healthi myometrium present putat mechan dysregul progesteron respons gene ul ensu loss rest use three rest condit knockout mous line provid comprehens pictur impact loss rest ul pathogenesi alter respons ul steroid hormon
|
D007889;D014594
|
T191
|
36,282,914
|
role gtp hydrolysi ef g ribosom transloc transloc transfer rna trna messeng rna mrna ribosom catalyz gtpase elong factor g ef g bacteria although guanosin triphosph gtp hydrolysi acceler transloc requir dissoci ef g fundament role remain unclear use ensembl frster reson energi transfer fret monitor inhibit gtp hydrolysi impact structur dynam ribosom use fret pair unambigu report rotat head domain l pair measur intersubunit rotat result show addit slow revers intersubunit rotat shown previous block gtp hydrolysi slow forward head rotat surpris block gtp hydrolysi complet abolish revers head rotat find l fret pair use previous studi monitor head rotat appear report almost exclus intersubunit rotat furthermor find signal quench termin pyren label mrna use extens follow mrna transloc correl close revers intersubunit rotat account find block gtp hydrolysi abolish rotat event occur movement mrna trnas essenti complet propos primari role gtp hydrolysi creat irrevers step mechan prevent releas ef g trnas mrna move one full codon ensur product transloc mainten translat read frame
|
D020653;D012270
|
T026;T126;T116
|
36,282,913
|
theta pattern stimul induc synapt intrins potenti lm interneuron brain oscil long last effect synapt cellular properti instanc synapt stimul theta frequenc induc persist depress excitatori synapt transmiss intrins excit ca princip neuron howev incid activ synapt transmiss intrins excit hippocamp gabaerg interneuron unclear report induct synapt intrins potenti orien lacunosum molecular lm interneuron follow stimul affer glutamaterg input frequenc rang hz long term synapt potenti ltp induc synapt activ calcium permeabl ampa receptor cp ampar wherea long term potenti intrins excit ltp ie result mglur depend regul kv voltag depend potassium channel hyperpolar activ cyclic nucleotid gate hcn channel deplet phosphatidylinositol biphosph pip ltp ltp ie revers demonstr synapt intrins chang bidirect lm cell conclud synapt activ frequenc induc synapt intrins potenti lm interneuron ie opposit typic seen glutamaterg neuron
|
D018091;D002118
|
T123;T121;T116;T192;T196
|
36,282,912
|
robust core architectur function brain network support topolog resili cognit perform middl old age adult age associ gradual chang cognit yet individu exhibit protect age relat cognit declin topolog characterist brain network promot protect cognit declin age unknown investig whether robust resili brain network queri via delin brain core network structur relat age cognit perform cross section dataset healthi middl old age adult n age first decompos subject function brain network use k shell decomposit found age negat associ robust core network structur next perturb network via attack simul found resili core brain network node also declin relationship age partit dataset middl age n old age n age subject observ older individu less robust core connect resili follow analys found episod memori posit relat robust connect core resili particular within default node limbic frontopariet control network import found age relat differ episod memori posit relat core resili indic potenti role core resili protect cognit declin togeth find suggest robust core connect resili brain network could facilit high cognit perform age
|
D008279;D001921
|
T060;T023;T170;T059
|
36,282,911
|
host protein kinas requir sar cov nucleocapsid phosphoryl viral replic multipl coronavirus emerg independ past year caus lethal human diseas although vaccin develop target virus acceler substanti remain patient requir treatment vaccin experi breakthrough infect understand common host factor necessari life cycl coronavirus may reveal conserv therapeut target use known substrat specif mammalian protein kinas deconvolut sequenc phosphoryl event mediat three host protein kinas famili srpk gsk ck coordin phosphoryl cluster serin threonin residu viral n protein requir viral replic also show loss inhibit srpk propos initi n protein phosphoryl cascad compromis viral replic cycl phosphoryl site high conserv across coronavirus inhibitor protein kinas may therapeut potenti covid also may broad use coronavirus mediat diseas
|
D000086402;D000086382
|
T005;T067;T047
|
36,282,910
|
yap taz promot osteogenesi prevent chondrogenesi neural crest cell vitro vivo neural crest cell nccs multipot stem cell differenti multipl cell type includ osteoblast chondrocyt constitut craniofaci skeleton show vitro vivo studi transcript regul yap taz redund function key determin specif differenti nccs osteoblast chondrocyt primari cultur nccs defici yap taz switch osteogenesi chondrogenesi ncc specif defici yap taz result bone loss ectop cartilag mice yap bound regulatori element key gene govern osteogenesi chondrogenesi nccs direct regul express gene also contain bind site tcflef transcript factor interact wnt effector catenin differenti nccs vitro ncc deriv osteogenesi vivo yap taz promot express osteogen gene runx sp repress express chondrogen gene sox cola furthermor yap taz interact catenin nccs coordin promot osteoblast differenti repress chondrogenesi togeth data indic yap taz promot osteogenesi nccs prevent chondrogenesi part interact wnt catenin pathway
|
D020219;D010012
|
T042
|
36,282,909
|
modul macrocycl peptid cell permeabl macrocycl peptid antagon either activ inact state g fine tune signal
|
D010455;D015398
|
T121;T116;T044;T043
|
36,282,905
|
immun mediat inflammatori diseas anti sar cov vaccin new diagnos diseas flare new onset immun mediat inflammatori diseas imid flare pre exist imid report follow anti sar cov vaccin studi aim describ retrospect cohort patient develop new onset imid flare known imid within day anti sar cov vaccin dose
|
D001327;D000086382;D014612
|
T129;T121;T116;T067;T047
|
36,282,904
|
ion dipol correct drism solvat model accur comput water distribut around negat charg biomolecul refer interact site model drism provid effici grid base solvat model comput structur thermodynam properti biomolecul aqueous solut howev remain challeng exist drism method correct predict water distribut around negat charg solut molecul paper first show challeng main due orient water molecul first solvat shell negat charg solut molecul proper consid orient prefer posit depend two bodi intramolecular correl solvent need includ drism theori direct evalu posit depend two bodi intramolecular correl remain numer intract address challeng introduc ion dipol correct idc drism theori incorpor orient prefer water molecul via addit solut solvent interact term ie ion dipol interact keep formul drism equat unchang prove newli introduc idc term equival effect direct correl function effect consid orient effect aris posit depend two bodi correl first quantit valid drism idc theori combin pse closur cl clo two site anion three site anion three anion show drism idc theori signific outperform drism theori accur predict solvat structur comparison md simul includ rdfs water distribut furthermor also demonstr drism idc improv accuraci hydrat free energi calcul cl demonstr drism idc theori yield signific improv drism theori appli comput solvat structur various negat charg solut molecul includ adenosin triphosph atp short peptid contain residu dna hairpin contain nucleotid riboswitch rna molecul nucleotid expect drism idc pse solvat model hold great promis wide appli studi solvat properti nucleic acid biomolecul contain negat charg function group
|
D014867;D009711
|
T121;T197;T114
|
36,282,903
|
treatment lisfranc injuri year old boy case report surgic techniqu case year old boy lisfranc injuri identifi weight bear film treat success close reduct clamp smooth pin fixat patient return sport without pain radiograph sign arthriti year
|
D050723;D004204
|
T037
|
36,282,902
|
popul dynam baltic herring sinc vike age reveal ancient dna genom world ocean current face major stressor form overexploit anthropogen climat chang baltic sea home first industri fisheri ago target baltic herring speci still econom cultur import today yet earli origin marin industri long term ecolog consequ histor contemporari fisheri remain debat studi long term popul dynam baltic herring evalu past impact human marin environ combin modern whole genom data ancient dna adna identifi earliest known long distanc herring trade region illustr extens fish trade began vike age resolv popul structur within baltic observ demograph independ four local herring stock least generat suggest overfish resund th centuri result demograph shift autumn spawn spring spawn herring domin baltic show resund fisheri negat impact western baltic herring stock demograph shift spring spawn domin occur th centuri instead demograph reconstruct reveal popul trajectori consist expect impact environment chang histor report shift fish target time studi illustr joint impact climat chang human exploit marin speci well role histor ecolog play conserv manag polici
|
D005398;D000072441
|
T092;T123;T114
|
36,282,893
|
slow progress toward pneumonia control children low middl incom countri measur pneumonia indic systemat review literatur integr global action plan prevent control pneumonia diarrhoea gappd goal end prevent childhood death pneumonia diarrhoea target indic monitor progress aim systemat review summaris low middl incom countri lmic report pneumonia specif gappd indic nation subnat level whether gappd target achiev
|
D003906;D011014
|
T047;T050;T080
|
36,282,892
|
singl nanoparticl count base liquid biopsi cancer diagnosi liquid biopsi becom sought techniqu diseas diagnosi provid real time dynam comprehens inform allevi dilemma face tissu biopsi multiplex microrna mirna demonstr promis biomark liquid biopsi fall short provid simpl sensit analyt method work establish novel nanoparticl count strategi accomplish simultan analysi three breast cancer associ mirna breast cancer diagnosi frequenc nanoparticl involv format sandwich structur detect singl particl induct coupl plasma mass spectrometri sp icpm quantifi target detect limit mir mir mir amol respect strategi appli clinic sampl success achiev diagnosi normal individu breast cancer patient area curv auc combin relat express mir mir result indic strategi potenti hold great promis play essenti role cancer diagnosi
|
D035683;D001943;D053758
|
T123;T191;T073;T114
|
36,282,886
|
fulli autom crispr lamp platform sar cov delta omicron variant integr cluster regular interspac short palindrom repeat crispr loop mediat amplif lamp technolog great import crispr base diagnost system urgent need develop improv diagnost accuraci labor free contamin free fulli autom droplet manipul platform crispr lamp technolog develop herein propos fulli autom crispr lamp platform precis manipul crispr lamp droplet perform combin reaction high sensit specif sar cov spike tk dg pr ph mutat typic point mutat b delta omicron variant monitor platform detect limit copiesl allel discrimin mutant wild type signific design onetwo mismatch crispr rna crrna limit copiesl chemic synthes modifi crrnas great increas crispr lamp signal advanc wide applic combin previous develop rdrp crispr lamp assay clinic result show spike tk ph discrimin mutant type form wild type confid interv confid interv sensit respect specif confid interv rdrp target detect sar cov strain sensit confid interv specif confid interv believ automat digit microfluid dmf system advanc integr crispr lamp technolog higher stabil sensit practic also crispr associ diagnost platform
|
D000086402;D000086382
|
T005;T067;T047
|
36,282,885
|
heart rate variabl risk heart failur subtyp post menopaus women women health initi studi low heart rate variabl hrv measur autonom imbal associ increas risk coronari heart diseas chd heart failur hf howev relationship hf subtyp heart failur preserv eject fraction hfpef heart failur reduc eject fraction hfref studi prior
|
D006333;D003327
|
T047;T046
|
36,282,884
|
adher low risk diseas public health measur covid pandem qualit studi public health measur phms proactiv reactiv reduc spread diseas measur target individu behaviour requir broad adher effect consequ world health organ issu special appeal young adult known non adher popul increas adher covid guidelin howev littl known low risk individu adher phms studi investig young adult low risk set adher phms implement covid pandem qualit research approach chosen gain depth understand particip thought experi relat phm adher semi structur interview conduct april may young adult live princ edward island pei provinc lowest covid case rate canada time themat analysi use creat codebook base theoret domain framework induct modifi analysi identifi eight theme explain adher young adult clear purpos driven adher rational develop trust local leadership adapt novel measur manag disrupt adher reduc anxieti collect duti toward one communiti moral culpabl use caution rather complianc togeth theme demonstr young adult adher phms sens connect communiti public health leadership concern stigma argu clear guidelin communic public health offici period high low covid case facilit adher find import mitig futur public health emerg explain young adult import segment popul whose adher critic success phms follow phms find inform public health offici stakehold aim develop success adher strategi
|
D000086382
|
T047;T067
|
36,282,879
|
risk cardiovascular diseas patient alcohol use disord popul base retrospect cohort studi complex effect alcohol consumpt cardiovascular system vari mean daili consumpt durat intak popul base retrospect cohort studi aim explor risk cardiovascular diseas cvd patient alcohol use disord aud data collect taiwan nation health insur research databas total patient aud includ studi group age sex match control without aud control group cox proport hazard regress analysi use investig effect aud risk cvd patient men age year end follow period aud group signific higher incid cvd vs p comorbid control group aud group also exhibit signific higher incid cvd control group base cox regress analysi fine gray compet risk model adjust hazard ratio ahr confid interv ci p furthermor male sex diabet mellitus hypertens hyperlipidemia chronic kidney diseas chronic obstruct pulmonari diseas anxieti depress high charlson comorbid index also associ increas risk cvd patient aud differ cvd subgroup cvd ischem heart diseas ihd stroke signific higher risk diseas without aud cvd ahr ci p ihd ahr ci p stroke ahr ci p risk also signific differ among patient differ cvd subgroup observ associ aud develop cvd even adjust sever comorbid medic nationwid popul cohort
|
D000437;D002318;D020521
|
T047;T048
|
36,282,878
|
molecular epidemiolog kaposi sarcoma virus spain sinc human herpesvirus hhv infect may underestim hhv subtyp circul spain remain unknown molecular epidemiolog studi high desir
|
D012514;D019288;D000163;D006566
|
T005;T191;T047
|
36,282,872
|
contact len safeti correct refract error healthi eye contact lens safe effect method correct refract error worn estim million american widespread avail commerci popular contact lens well appreci public contact lens us food drug administr fda regul medic devic contact lens market numer hard soft materi improv decad worn daili extend wear replac rang schedul daili year longer len materi wear care regimen impact risk contact len relat corneal inflammatori event microbi kerat articl review contact len safeti specif focus correct refract error healthi eye
|
D003261;D012030;D007634;D003262;D003263
|
T047;T074
|
36,282,866
|
funhop analysi reveal upregul mitochondri gene prostat cancer mitochondri activ cancer cell central cancer research sinc otto warburg first publish thesi topic although warburg propos oxid phosphoryl tricarboxyl acid tca cycl perturb cancer later research shown oxid phosphoryl activ cancer includ prostat cancer pca howev detail knowledg mitochondri metabol metabol pathway cancer still lack studi expand previous develop method analyz function homolog protein funhop provid detail view metabol pathway funhop use result differenti express analysi rna seq data improv pathway analysi ad inform subcellular local base experiment data comput predict use funhop differenti mitochondri non mitochondri process cancer normal prostat cell line result show mitochondri pathway upregul pca split metabol pathway mitochondri non mitochondri counterpart use funhop add interpret metabol properti pca cell
|
D050259;D011471
|
T045;T191;T028
|
36,282,865
|
signal valu drive engag multi round inform intervent inform intervent effect recipi must first engag show engag repeat digit inform intervent shape subtl strateg control signal inform valu particular recipi expect shape signal envelop surround messag inform intervent envelop convey clue messag reveal messag peopl expect messag valuabl deliv consist recogniz envelop time increas engag relat vari envelop convers peopl expect messag littl valu deliv consist recogniz envelop decreas engag relat vari envelop show two field experi involv massiv open onlin cours one onlin survey experi pre regist n
|
D011795
|
T098;T062;T170;T081;T057
|
36,282,864
|
interest without uptak mix method analysi methadon util kyrgyz prison hiv incid continu increas eastern europ central asia eeca larg part due non steril inject drug use especi within prison therefor medic assist therapi opioid agonist evid base hiv prevent strategi kyrgyz republ offer methadon within prison system uptak remain low screen brief intervent referr treatment sbirt framework identifi peopl would potenti benefit methadon interven identifi oud problem methadon potenti solut provid referr methadon treatment use sbirt framework screen oud kyrgyz prison among peopl within six month return communiti n enrol peopl oud studi alreadi engag methadon treatment conduct pre releas survey follow brief intervent bi address barrier methadon engag follow survey immedi intervent month month month prison releas assess methadon attitud uptak depth qualit interview particip explor factor influenc methadon util incarcer near particip indic favor attitud toward methadon intervent survey howev interest initi methadon treatment remain low bi qualit find identifi five factor negat influenc methadon uptak despit express posit attitud toward methadon interperson relationship interact crimin justic system logist concern crimin subcultur health relat concern
|
D011329;D009293;D000163
|
T047;T098;T048
|
36,282,862
|
next generat kras target reason excit concern develop select krasgc inhibitor direct inhibit kras oncogen histor thought undrugg repres watersh moment oncolog development therapeut kras target therapi move second phase signific excit anticip durabl diseas control tumor type option remain limit clinic trial test combin therapi indirect pan rasmap kinas pathway inhibitor activ state ras inhibitor howev also reason caution regard safeti toler expand ras inhibit evidenc intoler combin therapi select krasgc inhibitor foreshadow prior failur combin therapi oncogen driven tumor herein review landscap outlook kras target therapi specif focus upon strategi combat resist kras target therapi discuss possibl target unanticip target effect may limit clinic use
|
D016283;D000970
|
T121;T126;T116;T109
|
36,282,861
|
role npm altern splice patient chronic lymphocyt leukemia chronic lymphocyt leukemia cll lymphoprolif diseas heterogen clinic cours recent studi reveal link notch mutat overexpress myc myc relat gene involv ribosom biogenesi protein biosynthesi nucleophosmin npm cll cell present studi aim evalu impact notch mutat myc myc induc npm express cll cell via quantif transcript
|
D015451
|
T191
|
36,282,860
|
perceiv listen abil hear loss systemat review qualit meta synthesi hear loss hl affect communic complex way understand adult hl reflect conceptualis way listen metacognit requir intervent outcom measur use evalu address barrier function communic aris hl
|
D034381;D003638
|
T033;T184;T047
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.